Image-guided radiation therapy vendor ViewRay announced its revenue for the third quarter was nearly half of what it was a year ago.
For the quarter (end-September 30), the firm posted revenue of $10.1 million, down 52% compared with revenue of $20.9 million in the same period the year before. The company's net loss for the most recent period was $28.1 million, compared with a net loss of $20.8 million in the third quarter of fiscal 2019.
Despite the results, ViewRay's President and CEO Scott Drake said the company was pleased with the third-quarter results in light of the economic backdrop. In part, that's because ViewRay received its first order from the U.S. Department of Veterans Affairs in the third quarter.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
